A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of Type 2 diabetes

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.1, Iss.7, 2000-12, pp. : 1455-1467

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Repaglinide: A Pharmacoeconomic Review of its Use in Type 2 Diabetes Mellitus

By Plosker G.L. Figgitt D.P.

PharmacoEconomics, Vol. 22, Iss. 6, 2004-01 ,pp. : 389-411

Adis International

Access to resources Recommend Favorite

Defining the Role of Repaglinide in the Management of Type 2 Diabetes Mellitus: A Review

By Odd Erik Johansen

American Journal of Cardiovascular Drugs, Vol. 7, Iss. 5, 2007-01 ,pp. : 319-335

Adis International

Access to resources Recommend Favorite

Repaglinide: A Review of its Therapeutic Use in Type 2 Diabetes Mellitus

By Culy C.R. Jarvis B.

Drugs, Vol. 61, Iss. 11, 2001-01 ,pp. : 1625-1660

Adis International

Access to resources Recommend Favorite

Repaglinide: A Review of Its Use in Type 2 Diabetes Mellitus

By Scott Lesley J.

Drugs, Vol. 72, Iss. 2, 2012-01 ,pp. : 249-272

Adis International

Access to resources Recommend Favorite

In Finland, repaglinide is dominant to nateglinide as combination therapy with metformin for the treatment of type 2 diabetes mellitus inadequately controlled with monotherapy

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 507, 2006-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite